Xue Z, Han M, Sun T, Wu Y, Xing W, Mu F
Theranostics. 2025; 15(2):745-765.
PMID: 39744686
PMC: 11671384.
DOI: 10.7150/thno.102597.
Ren Y, Liu Y, Pang R, Xu G, Lei Y, Kwok H
Front Cell Infect Microbiol. 2024; 14:1502770.
PMID: 39679197
PMC: 11638163.
DOI: 10.3389/fcimb.2024.1502770.
Roy A, Cheriyan B, Perumal E, Rengasamy K, Anandakumar S
Odontology. 2024; .
PMID: 39540968
DOI: 10.1007/s10266-024-01020-1.
Karati D, Saha A, Roy S, Mukherjee S
Curr Top Med Chem. 2024; 24(28):2489-2508.
PMID: 39297470
DOI: 10.2174/0115680266321659240906114742.
Sun Y, Xu Q, Dai D, Wang S, Li X, Shi S
iScience. 2024; 27(7):110280.
PMID: 39055921
PMC: 11269306.
DOI: 10.1016/j.isci.2024.110280.
Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.
Meur S, Mukherjee S, Roy S, Karati D
Mol Neurobiol. 2024; 61(12):10941-10955.
PMID: 38816674
DOI: 10.1007/s12035-024-04257-7.
Antitumor activity of the protein kinase inhibitor 1-(β-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
Koronkiewicz M, Kazimierczuk Z, Orzeszko A
BMC Cancer. 2022; 22(1):1069.
PMID: 36243702
PMC: 9571492.
DOI: 10.1186/s12885-022-10156-8.
Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.
Zhang W, Huang C, Liu J, Wu L, Zhang H, Wu X
Dis Markers. 2022; 2022:6441139.
PMID: 35937947
PMC: 9355762.
DOI: 10.1155/2022/6441139.
PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
Mahata S, Sahoo P, Pal R, Sarkar S, Mistry T, Ghosh S
Med Oncol. 2022; 39(5):74.
PMID: 35568774
DOI: 10.1007/s12032-022-01675-2.
PDGF-BB promotes vascular smooth muscle cell migration by enhancing Pim-1 expression via inhibiting miR-214.
Zhou J, Shao L, Yu J, Huang J, Feng Q
Ann Transl Med. 2022; 9(23):1728.
PMID: 35071422
PMC: 8743727.
DOI: 10.21037/atm-21-5638.
An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer.
Sanchez-Martin V, Lopez-Pujante C, Soriano-Rodriguez M, Garcia-Salcedo J
Int J Mol Sci. 2020; 21(23).
PMID: 33255335
PMC: 7734589.
DOI: 10.3390/ijms21238900.
PIM1 Promotes Survival of Cardiomyocytes by Upregulating c-Kit Protein Expression.
Ebeid D, Firouzi F, Esquer C, Navarrete J, Wang B, Gude N
Cells. 2020; 9(9).
PMID: 32878131
PMC: 7563506.
DOI: 10.3390/cells9092001.
Anti-Inflammatory Effects of the Novel PIM Kinase Inhibitor KMU-470 in RAW 264.7 Cells through the TLR4-NF-κB-NLRP3 Pathway.
Baek H, Min H, Hong V, Kwon T, Park J, Lee J
Int J Mol Sci. 2020; 21(14).
PMID: 32698512
PMC: 7403980.
DOI: 10.3390/ijms21145138.
Pim-1 Protects Retinal Ganglion Cells by Enhancing Their Regenerative Ability Following Optic Nerve Crush.
Zhang S, Shuai L, Wang D, Huang T, Yang S, Miao M
Exp Neurobiol. 2020; 29(3):249-272.
PMID: 32624507
PMC: 7344373.
DOI: 10.5607/en20019.
PIM-1 kinase: a potential biomarker of triple-negative breast cancer.
Chen J, Tang G
Onco Targets Ther. 2019; 12:6267-6273.
PMID: 31496730
PMC: 6690594.
DOI: 10.2147/OTT.S212752.
Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis.
Arrouchi H, Lakhlili W, Ibrahimi A
Bioinformation. 2019; 15(2):116-120.
PMID: 31435157
PMC: 6677905.
DOI: 10.6026/97320630015116.
Safety profiling of genetically engineered Pim-1 kinase overexpression for oncogenicity risk in human c-kit+ cardiac interstitial cells.
Broughton K, Korski K, Echeagaray O, Adamson R, Dembitsky W, Lu Z
Gene Ther. 2019; 26(7-8):324-337.
PMID: 31239537
DOI: 10.1038/s41434-019-0084-5.
Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds.
Ikram N, Mirza M, Vanmeert M, Froeyen M, Salo-Ahen O, Tahir M
Biomolecules. 2019; 9(4).
PMID: 30925835
PMC: 6523505.
DOI: 10.3390/biom9040124.
The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
Stafman L, Waldrop M, Williams A, Aye J, Stewart J, Mroczek-Musulman E
J Pediatr Surg. 2019; 54(6):1206-1213.
PMID: 30898394
PMC: 6545248.
DOI: 10.1016/j.jpedsurg.2019.02.029.
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J, Sha Y, Roof L, Foreman O, Lazarchick J, Venkta J
Cancer Lett. 2018; 440-441:1-10.
PMID: 30312729
PMC: 6290736.
DOI: 10.1016/j.canlet.2018.10.003.